Asciminib - ABL001

Based on 56 reference(s) in Google Scholar 8 10 56

Axon 2757

CAS [1492952-76-7]

MF C20H18ClF2N5O3
MW 449.84

  • Purity: 98%
  • Optical purity: 100% e.e.
  • Soluble in 0.1N HCl(aq), DMSO and EtOH
Recently added

Asciminib

Description

Asciminib is a potent and selective allosteric BCR-ABL1 inhibitor with an IC50 value of 0.5 nM (caliper assay). Moreover, Asciminib is the first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor. In vivo, the combination of ABL001 and Nilotinib (Axon 1396) led to complete disease control and eradicated CML xenograft tumours without recurrence after the cessation of treatment.

KEYWORDS: Asciminib | Supplier | Bcr-Abl inhibitor | ABL001 | ABL-001 | ABL 001 | CAS [1492952-76-7] | [2119669-71-3] | [2679814-62-9] | Non Selective (Phosphorylation substrates) | BCR-ABL | Inhibitor | Enzymes | Chronic myeloid leukaemia | CML | BCR-ABL1 fusion oncoprotein | Specifically Targeting the ABL Myristoyl Pocket

Order
Size Unit Price Stock
5 mg €120.00 In Stock
25 mg €400.00 In Stock
Special Offers
Size Unit Price Stock
2 x 5 mg €200.00 In Stock
2 x 25 mg €600.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...